Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Swiss National Bank

Swiss National Bank boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 28.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 78,200 shares of the company’s stock after purchasing an additional 17,200 shares during the period. Swiss National Bank owned approximately 0.14% of Harmony Biosciences worth $2,691,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ruffer LLP acquired a new stake in Harmony Biosciences in the 4th quarter valued at about $2,598,000. Amundi lifted its stake in Harmony Biosciences by 243.3% during the fourth quarter. Amundi now owns 18,402 shares of the company’s stock valued at $635,000 after purchasing an additional 13,041 shares during the last quarter. Capital Management Corp VA boosted its holdings in Harmony Biosciences by 43.5% during the fourth quarter. Capital Management Corp VA now owns 340,960 shares of the company’s stock worth $11,732,000 after buying an additional 103,308 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock worth $80,000 after buying an additional 519 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Harmony Biosciences in the fourth quarter valued at $1,304,000. 86.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock valued at $2,831,679 in the last three months. Insiders own 30.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HRMY shares. HC Wainwright decreased their target price on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, February 25th. Finally, Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday, March 18th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $53.33.

Harmony Biosciences Stock Performance

HRMY stock opened at $33.35 on Friday. The firm has a 50 day simple moving average of $36.13 and a 200 day simple moving average of $35.52. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The stock has a market cap of $1.91 billion, a P/E ratio of 15.81, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.74 by $0.11. The business had revenue of $201.30 million for the quarter, compared to analysts’ expectations of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.45 EPS. Research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.